Why the study?
Do new P2Y12 inhibitors (prasugrel and ticagrelor) improve ischemic outcomes compared with clopidogrel in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes, including those after percutaneous coronary intervention with…
Comparison
New P2Y12 inhibitors (prasugrel and ticagrelor) vs Standard-dose clopidogrel
Design
Review
Authors
Loading...
Supports prasugrel or ticagrelor for net benefit in higher-risk ACS; leaves open optimal selection and bleeding management.
Do new P2Y12 inhibitors (prasugrel and ticagrelor) improve ischemic outcomes compared with clopidogrel in patients with acute coronary syndromes?
Prasugrel and ticagrelor offer superior ischemic protection and better net clinical benefit compared to clopidogrel for secondary prevention in patients with acute coronary syndromes, despite a higher bleeding risk.
Silvain et al. (2011) studied this question.